Boehringer Ingelheim
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
July 21, 2025Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …
Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
June 30, 2025Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics
Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
July 30, 2024Mergers and Acquisitions Boehringer Ingelheim, Nerio Therapeutics, Oncology, immuno-oncology, oncology
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …
Brainomix and Boehringer Ingelheim enter strategic partnership
July 19, 2024Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …
OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments
May 24, 2024Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
March 20, 2024Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
February 26, 2024Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
September 25, 2023Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …
Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal
May 9, 2023Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets
German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …
Researchers and pharma companies partner to investigate new schizophrenia treatment
January 21, 2021Biogen, Boehringer Ingelheim
The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …
Boehringer Ingelheim and Enara Bio to collaborate on cancer immunotherapies
January 12, 2021Manufacturing and Production Boehringer Ingelheim, Cancer, Enara Bio
Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted …
Boehringer’s nintedanib approved in Europe for systemic sclerosis-associated interstitial lung disease
April 22, 2020Research and Development, Sales and Marketing Boehringer Ingelheim, EU, nintedanib, pharma
The European Commission has moved to authorise Boehringer Ingelheim’s nintedanib in Europe for the treatment of systemic sclerosis-associated interstitial lung …
FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes
November 14, 2019Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma
Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …
Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease
September 10, 2019Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease
Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …
Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
September 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
Latest content
Five Facts about cardiovascular disease
